• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

种族多样化的 Medicare 受益人群中痴呆症诊断和专业护理的纵向分析。

Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries.

机构信息

Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins, Baltimore, MD, USA.

Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA, USA.

出版信息

Alzheimers Dement. 2019 Nov;15(11):1402-1411. doi: 10.1016/j.jalz.2019.07.005. Epub 2019 Sep 4.

DOI:10.1016/j.jalz.2019.07.005
PMID:31494079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6874742/
Abstract

INTRODUCTION

There is insufficient understanding of diagnosis of etiologic dementia subtypes and contact with specialized dementia care among older Americans.

METHODS

We quantified dementia diagnoses and subsequent health care over five years by etiologic subtype and physician specialty among Medicare beneficiaries with incident dementia diagnosis in 2008/09 (226,604 persons/714,015 person-years).

RESULTS

Eighty-five percent of people were diagnosed by a nondementia specialist physician. Use of dementia specialists within one year (22%) and five years (36%) of diagnosis was low. "Unspecified" dementia diagnosis was common, higher among those diagnosed by nondementia specialists (33.2%) than dementia specialists (21.6%). Half of diagnoses were Alzheimer's disease.

DISCUSSION

Ascertainment of etiologic dementia subtype may inform hereditary risk and facilitate financial and care planning. Use of dementia specialty care was low, particularly for Hispanics and Asians, and associated with more detection of etiological subtype. Dementia-related professional development for nonspecialists is urgent given their central role in dementia diagnosis and care.

摘要

简介

美国老年人对病因性痴呆亚型的诊断以及与专门的痴呆护理的接触了解不足。

方法

我们在 2008/09 年(226,604 人/714,015 人年)期间,对患有偶发性痴呆诊断的医疗保险受益人,按病因亚型和医生专业对五年内的诊断和随后的医疗保健进行了量化。

结果

85%的人是由非痴呆症专家医生诊断的。在诊断后一年内(22%)和五年内(36%)使用痴呆症专家的比例较低。“未特指”的痴呆诊断很常见,在由非痴呆症专家诊断的患者中(33.2%)比痴呆症专家(21.6%)更高。一半的诊断为阿尔茨海默病。

讨论

病因性痴呆亚型的确定可以提供遗传风险信息,并有助于财务和护理规划。痴呆症专科护理的使用率较低,尤其是西班牙裔和亚洲人,且与病因亚型的检出率更高相关。鉴于非专家在痴呆症诊断和护理中的核心作用,对他们进行痴呆症相关的专业发展是当务之急。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/510d210e2b96/nihms-1535362-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/e22e653ffba4/nihms-1535362-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/d2b3e58d99b0/nihms-1535362-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/7613c9401e22/nihms-1535362-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/510d210e2b96/nihms-1535362-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/e22e653ffba4/nihms-1535362-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/d2b3e58d99b0/nihms-1535362-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/7613c9401e22/nihms-1535362-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6911/6874742/510d210e2b96/nihms-1535362-f0004.jpg

相似文献

1
Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries.种族多样化的 Medicare 受益人群中痴呆症诊断和专业护理的纵向分析。
Alzheimers Dement. 2019 Nov;15(11):1402-1411. doi: 10.1016/j.jalz.2019.07.005. Epub 2019 Sep 4.
2
Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013.2011 - 2013年美国医疗保险按服务收费受益人群中痴呆症亚型的患病率。
Alzheimers Dement. 2017 Jan;13(1):28-37. doi: 10.1016/j.jalz.2016.04.002. Epub 2016 May 10.
3
2021 Alzheimer's disease facts and figures.2021 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2021 Mar;17(3):327-406. doi: 10.1002/alz.12328. Epub 2021 Mar 23.
4
Receipt of Eye Care Services among Medicare Beneficiaries with and without Dementia.有和没有痴呆症的 Medicare 受益人的眼科保健服务的获得情况。
Ophthalmology. 2020 Aug;127(8):1000-1011. doi: 10.1016/j.ophtha.2020.02.022. Epub 2020 Feb 25.
5
The costs of dementia subtypes to California Medicare fee-for-service, 2015.2015 年加利福尼亚医疗保险按服务收费模式下各痴呆亚型的成本。
Alzheimers Dement. 2019 Jul;15(7):899-906. doi: 10.1016/j.jalz.2019.03.015. Epub 2019 Jun 4.
6
Medicare physician referral patterns.医疗保险医师转诊模式。
Health Serv Res. 1999 Apr;34(1 Pt 2):331-48.
7
Health care utilization before and after a dementia diagnosis in Medicare Advantage versus traditional Medicare.医疗保险优势计划与传统医疗保险中痴呆症诊断前后的医疗保健利用情况。
J Am Geriatr Soc. 2024 Jun;72(6):1856-1866. doi: 10.1111/jgs.18570. Epub 2023 Sep 5.
8
2022 Alzheimer's disease facts and figures.2022 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2022 Apr;18(4):700-789. doi: 10.1002/alz.12638. Epub 2022 Mar 14.
9
The generalist role of specialty physicians: is there a hidden system of primary care?专科医生的通才角色:是否存在一个隐藏的初级保健体系?
JAMA. 1998 May 6;279(17):1364-70. doi: 10.1001/jama.279.17.1364.
10
Relationship of Neighborhood Greenness to Alzheimer's Disease and Non-Alzheimer's Dementia Among 249,405 U.S. Medicare Beneficiaries.249405 名美国医疗保险受益人与阿尔茨海默病和非阿尔茨海默病痴呆症的邻里绿地关系。
J Alzheimers Dis. 2021;81(2):597-606. doi: 10.3233/JAD-201179.

引用本文的文献

1
A Real-World Analysis of the Clinical Journey, Diagnosis, and Monitoring Patterns of Patients With Alzheimer Disease by Stage in the United States.美国阿尔茨海默病患者按阶段划分的临床病程、诊断及监测模式的真实世界分析
Am J Alzheimers Dis Other Demen. 2025 Jan-Dec;40:15333175251375378. doi: 10.1177/15333175251375378. Epub 2025 Sep 12.
2
The National Dementia Workforce Study: Methods for Surveying Community Clinicians Who Provide Care to People With Dementia.国家痴呆症劳动力研究:对为痴呆症患者提供护理的社区临床医生进行调查的方法。
J Am Geriatr Soc. 2025 Aug 8. doi: 10.1111/jgs.70037.
3
Identifying dementia neuropathology using low-burden clinical data.

本文引用的文献

1
Health Care Utilization and Cost Outcomes of a Comprehensive Dementia Care Program for Medicare Beneficiaries.医疗保险受益人的综合痴呆症护理计划的医疗保健利用和成本结果。
JAMA Intern Med. 2019 Feb 1;179(2):161-166. doi: 10.1001/jamainternmed.2018.5579.
2
The Impact of Changes in Population Health and Mortality on Future Prevalence of Alzheimer's Disease and Other Dementias in the United States.人口健康和死亡率变化对美国未来阿尔茨海默病和其他类型痴呆症流行率的影响。
J Gerontol B Psychol Sci Soc Sci. 2018 Apr 16;73(suppl_1):S38-S47. doi: 10.1093/geronb/gbx147.
3
Impairment of memory generalization in preclinical autosomal dominant Alzheimer's disease mutation carriers.
利用低负荷临床数据识别痴呆症神经病理学
Alzheimers Dement. 2025 Aug;21(8):e70539. doi: 10.1002/alz.70539.
4
Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons With Dementia.布雷哌唑在痴呆症患者中的使用情况以及6个月死亡率、住院率和急诊就诊率的真实世界证据。
Neurology. 2025 Aug 12;105(3):e213717. doi: 10.1212/WNL.0000000000213717. Epub 2025 Jul 3.
5
Implementation of a virtual dementia system of care in a VA health setting.在退伍军人事务部(VA)医疗环境中实施虚拟痴呆症护理系统。
BMC Geriatr. 2025 May 28;25(1):380. doi: 10.1186/s12877-025-06034-0.
6
Global multi-specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers.全球多专科临床医生对阿尔茨海默病血液生物标志物实施情况的看法。
Alzheimers Dement. 2025 May;21(5):e70201. doi: 10.1002/alz.70201.
7
Feasibility and Acceptability of Implementing a Digital Cognitive Assessment for Alzheimer Disease and Related Dementias in Primary Care.在初级保健中实施针对阿尔茨海默病及相关痴呆症的数字认知评估的可行性和可接受性。
Ann Fam Med. 2025 May 27;23(3):191-198. doi: 10.1370/afm.240293.
8
Prevalence of dementia diagnoses in a safety net health system.安全网医疗系统中痴呆症诊断的患病率。
Alzheimers Dement. 2025 Apr;21(4):e70174. doi: 10.1002/alz.70174.
9
Assessing diagnostic performance of plasma biomarkers in Alzheimer's disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts.评估血浆生物标志物在阿尔茨海默病与认知未受损个体中的诊断性能:在中国队列中,磷酸化tau217成为最佳标志物。
Front Aging Neurosci. 2025 Mar 26;17:1554805. doi: 10.3389/fnagi.2025.1554805. eCollection 2025.
10
Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations.阿尔茨海默病基于血液的生物标志物检测:基于利益相关者的覆盖范围考量评估
J Alzheimers Dis. 2025 May;105(2):433-442. doi: 10.1177/13872877251329394. Epub 2025 Apr 1.
临床前常染色体显性阿尔茨海默病突变携带者的记忆泛化损伤。
Neurobiol Aging. 2018 May;65:149-157. doi: 10.1016/j.neurobiolaging.2018.01.022. Epub 2018 Feb 8.
4
The New National Provider Identifier.新的国家提供者识别码。
J Oncol Pract. 2006 Nov;2(6):281. doi: 10.1200/JOP.2006.2.6.281.
5
Signs and symptoms preceding the diagnosis of Alzheimer's disease: a systematic scoping review of literature from 1937 to 2016.阿尔茨海默病诊断前的体征和症状:对1937年至2016年文献的系统综述
BMJ Open. 2017 Aug 28;7(8):e015746. doi: 10.1136/bmjopen-2016-015746.
6
2016 Alzheimer's disease facts and figures.2016 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2016 Apr;12(4):459-509. doi: 10.1016/j.jalz.2016.03.001.
7
Assessing the economic burden of Alzheimer's disease patients first diagnosed by specialists.评估首次由专科医生诊断的阿尔茨海默病患者的经济负担。
BMC Geriatr. 2016 Jul 11;16:138. doi: 10.1186/s12877-016-0303-5.
8
Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study.美国抗痴呆药物的治疗模式:医疗保险队列研究
J Am Geriatr Soc. 2016 Aug;64(8):1540-8. doi: 10.1111/jgs.14226. Epub 2016 Jun 24.
9
The Value of Delaying Alzheimer's Disease Onset.延迟阿尔茨海默病发病的价值。
Forum Health Econ Policy. 2014 Nov;18(1):25-39. doi: 10.1515/fhep-2014-0013. Epub 2014 Nov 4.
10
Inequalities in dementia incidence between six racial and ethnic groups over 14 years.14年间六个种族和民族群体在痴呆症发病率上的不平等。
Alzheimers Dement. 2016 Mar;12(3):216-24. doi: 10.1016/j.jalz.2015.12.007. Epub 2016 Feb 11.